Trending Stock News

Arrowpoint Asset Management Trimmed Revance Therapeutics (RVNC) Position By $13.96 Million; TT Electronics plc (LON:TTG) Had 7 Bullish Analysts

TT Electronics plc (LON:TTG) Logo

Among 7 analysts covering TT Electronics PLC (LON:TTG), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. TT Electronics PLC had 62 analyst reports since August 20, 2015 according to SRatingsIntel. Numis Securities upgraded TT Electronics plc (LON:TTG) rating on Wednesday, May 11. Numis Securities has “Buy” rating and GBX 170 target. Liberum Capital maintained the stock with “Buy” rating in Friday, May 12 report. As per Wednesday, August 24, the company rating was upgraded by Canaccord Genuity. Jefferies maintained the stock with “Buy” rating in Thursday, February 22 report. On Thursday, February 11 the stock rating was maintained by Investec with “Hold”. Peel Hunt maintained TT Electronics plc (LON:TTG) on Tuesday, March 14 with “Buy” rating. The firm has “Buy” rating given on Monday, November 20 by Numis Securities. Numis Securities reinitiated it with “Buy” rating and GBX 260 target in Friday, August 11 report. The firm has “Buy” rating by Liberum Capital given on Wednesday, April 12. The rating was maintained by Jefferies on Monday, March 13 with “Buy”. See TT Electronics plc (LON:TTG) latest ratings:

09/04/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 Maintain
12/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 245.00 New Target: GBX 265.00 Maintain
08/03/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
08/03/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 Maintain
22/02/2018 Broker: Jefferies Rating: Buy Old Target: GBX 200.00 New Target: GBX 255.00 Maintain
15/02/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
14/02/2018 Broker: Numis Securities Rating: Buy Old Target: GBX 260.00 New Target: GBX 260.00 Maintain
12/01/2018 Broker: Liberum Capital Rating: Buy Old Target: GBX 240.00 New Target: GBX 240.00 Maintain
05/12/2017 Broker: Numis Securities Rating: Buy Old Target: GBX 260.00 New Target: GBX 260.00 Maintain
21/11/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 275.00 New Target: GBX 275.00 Maintain

Arrowpoint Asset Management Llc decreased Revance Therapeutics Inc (RVNC) stake by 18.67% reported in 2017Q4 SEC filing. Arrowpoint Asset Management Llc sold 398,787 shares as Revance Therapeutics Inc (RVNC)’s stock declined 12.21%. The Arrowpoint Asset Management Llc holds 1.74M shares with $62.09M value, down from 2.14M last quarter. Revance Therapeutics Inc now has $1.18B valuation. The stock decreased 1.68% or $0.55 during the last trading session, reaching $32.2. About 178,610 shares traded. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 51.24% since April 16, 2017 and is uptrending. It has outperformed by 39.69% the S&P500.

Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on May, 8. They expect $-0.69 EPS, up 26.60% or $0.25 from last year’s $-0.94 per share. After $-1.14 actual EPS reported by Revance Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -39.47% EPS growth.

Arrowpoint Asset Management Llc increased Msc Indl Direct Inc (NYSE:MSM) stake by 213,957 shares to 1.80M valued at $173.87 million in 2017Q4. It also upped Heritage Crystal Clean Inc (NASDAQ:HCCI) stake by 286,196 shares and now owns 2.29M shares. Umpqua Hldgs Corp (NASDAQ:UMPQ) was raised too.

Since October 18, 2017, it had 1 insider purchase, and 6 sales for $2.77 million activity. SILVERNAIL LAUREN P sold $105,839 worth of Revance Therapeutics, Inc. (NASDAQ:RVNC) on Thursday, March 22. 5,333 shares were sold by GARDNER PHYLLIS, worth $168,045. Another trade for 6,452 shares valued at $204,148 was sold by Browne L Daniel. Vickers Philip J. had bought 3,150 shares worth $98,393 on Friday, March 16.

Among 13 analysts covering Revance Therapeutics (NASDAQ:RVNC), 11 have Buy rating, 0 Sell and 2 Hold. Therefore 85% are positive. Revance Therapeutics had 29 analyst reports since August 22, 2015 according to SRatingsIntel. Piper Jaffray maintained it with “Buy” rating and $2800 target in Tuesday, July 25 report. The rating was maintained by Cantor Fitzgerald on Thursday, November 16 with “Buy”. The stock of Revance Therapeutics, Inc. (NASDAQ:RVNC) has “Buy” rating given on Thursday, June 8 by Aegis Capital. SunTrust maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) on Friday, December 8 with “Buy” rating. The firm earned “Buy” rating on Tuesday, December 5 by Guggenheim. The company was downgraded on Tuesday, January 9 by Guggenheim. As per Thursday, April 12, the company rating was maintained by Cantor Fitzgerald. On Monday, March 5 the stock rating was initiated by Goldman Sachs with “Buy”. Barclays Capital initiated it with “Buy” rating and $31.0 target in Monday, November 27 report. The stock has “Buy” rating by Mizuho on Wednesday, December 6.

Investors sentiment increased to 2.8 in Q4 2017. Its up 1.80, from 1 in 2017Q3. It improved, as 6 investors sold RVNC shares while 19 reduced holdings. 31 funds opened positions while 39 raised stakes. 31.34 million shares or 15.17% more from 27.21 million shares in 2017Q3 were reported. Pnc Fincl reported 0% stake. Parametric Portfolio Associates Ltd reported 0% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC). Fred Alger Mgmt invested in 25,000 shares or 0% of the stock. Voya Invest Management Llc reported 10,392 shares stake. Waddell Reed has 63,900 shares for 0.01% of their portfolio. Morgan Stanley, New York-based fund reported 228,008 shares. Perceptive Limited Liability Corp owns 400,000 shares. D E Shaw And holds 44,172 shares. 1492 Capital Mngmt Ltd Com invested in 1.09% or 38,966 shares. Northern Trust Corporation owns 301,405 shares. Schwab Charles reported 118,309 shares or 0% of all its holdings. Vanguard accumulated 0% or 1.24M shares. Trexquant Investment Limited Partnership holds 0.03% of its portfolio in Revance Therapeutics, Inc. (NASDAQ:RVNC) for 6,820 shares. Comml Bank Of Mellon has 2.14M shares for 0.02% of their portfolio. Rothschild Asset Mgmt Incorporated invested 0.02% in Revance Therapeutics, Inc. (NASDAQ:RVNC).

TT Electronics plc provides engineered electronics for performance critical applications worldwide. The company has market cap of 325.13 million GBP. It operates in four divisions: Transportation Sensing and Control, Industrial Sensing and Control, Advanced Components, and Integrated Manufacturing Services. It has a 7.27 P/E ratio. The Transportation Sensing and Control segment develops sensors and control solutions, including gear position and pedal sensors, and fluid and emission sensors for automotive original equipment manufacturers and suppliers, including powertrain suppliers of automotive, such as passenger cars and trucks.

The stock decreased 0.71% or GBX 1.5 during the last trading session, reaching GBX 209.5. About 34,064 shares traded. TT Electronics plc (LON:TTG) has 0.00% since April 16, 2017 and is . It has underperformed by 11.55% the S&P500.

Revance Therapeutics, Inc. (NASDAQ:RVNC) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *